BRIEF-Vexim says Anvisa approves Spinejack implants in Brazil
* HAS RECEIVED REGULATORY APPROVAL FROM ANVISA(1), BRAZIL'S NATIONAL HEALTH SURVEILLANCE AGENCY, IN ORDER TO COMMERCIALIZE SPINEJACK® IN BRAZIL.
April 10 Sichuan Maccura Biotechnology Co Ltd :
* Sees net profit for Q1 2017 to increase by 10 percent to 25 percent, or to be 75.5 million yuan to 85.8 million yuan, compared to net profit of the same period in 2016 (68.7 million yuan)
* Comments that product development is the main reason for the forecast
Source text in Chinese: goo.gl/2FaC3Y
Further company coverage: (Beijing Headline News)
SAO PAULO, May 29 Brazilian healthcare services provider Notre Dame Intermédica Sistema de Saúde SA on Monday filed for regulatory clearance to launch an initial public offering, the latest in a wave of stock listings in Latin America's largest economy after a years-long drought.